Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 408 full-time employees. The company went IPO on 2019-10-11. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. The company also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. The company also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Follow-Up Questions
Who is the CEO of Vir Biotechnology Inc?
Dr. Marianne De Backer is the Chief Executive Officer of Vir Biotechnology Inc, joining the firm since 2023.
What is the price performance of VIR stock?
The current price of VIR is $5.14, it has decreased 0.67% in the last trading day.
What are the primary business themes or industries for Vir Biotechnology Inc?
Vir Biotechnology Inc belongs to Biotechnology industry and the sector is Health Care
What is Vir Biotechnology Inc market cap?
Vir Biotechnology Inc's current market cap is $714.7M
Is Vir Biotechnology Inc a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for Vir Biotechnology Inc, including 3 strong buy, 9 buy, 1 hold, 0 sell, and 3 strong sell
